A Very interesting Hemp, and CBD firm that we have discovered is CIIX. CIIX it appears is positioning itself to become China’s GW Pharma. Just look at the massive news the company released today. If you are discovering CIIX for the first time, start your own research immediately, the company is under the radar, and could attract significant attention from the street at any time. CIIX has a hemp and cbd products retail store just outside of Los Angeles, Ca., and is looking to expand into mainland China. Those that find CIIX before it’s expansion could be in store for a great ride.
Here are the stocks investors looking to profit off marijuana should be looking at: ChineseInvestors.com, Inc. (CIIX), GW Pharmaceuticals (GWPH), Cronos Group (CRON), and CV Sciences, Inc. (CVSI)
ChineseInvestors.com, Inc. (CIIX)
Market Cap: $17.34M Share Price: $0.625
ChineseInvestors.com, Inc. (CIIX), the premier financial information website for Chinese-speaking investors, announced that its wholly owned foreign enterprise, CBD Biotechnology Co. Ltd., has launched a two-tier, direct selling initiative to accelerate its CBD sales into China. In addition, the Company has appointed marketing expert Mr. Fengxian Xie as President of its CBD Community Center, effective immediately. The goal of the CBD Community Center initiative is to establish a new, effective marketing channel to further stimulate demand for CBD Biotech’s innovative CBD-infused skin care products.
Skin care is not the only vertical CIIX’s CBD arm is focused on. Epilepsy is a large problem in China, affecting nearly 10 million epilepsy patients. Epilepsy is one of the most common diseases that the Chinese people are concerned about, making treatments and cures in the arena very interesting to Chinese speaking investors.
In the US, epilepsy can be cured by a high-risk surgical treatment. Due to the high-risk factor associated Chinese patients rely on conservative treatments, which is in line with how the disease is treated in China. CBD would be the best of both worlds for Chinese patients worldwide.
CIIX is well positioned to become China’s GW Pharma.
GW Pharmaceuticals, Inc. (GWPH)
Market Cap: $3.80B Share Price: $135.07
GW Pharmaceuticals, Inc. (GWPH), and its FDA approved product Epidiolex, have set a high bar when it comes to CBD firms. With the Fall months steadily approaching, we would not be surprised to see this stock skyrocket to new all time highs.
Cronos Group Inc. (NASDAQ: CRON)
Market Cap: $2.13B, current share price: $12.04
Cronos Group Inc., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marijuana for Medical Purposes Regulations. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights.
CV Sciences, Inc. (CVSI)
Market Cap: $447M Share Price: $4.94
CV Sciences (CVSI) has received more positive attention after it announced that it had appointed Joseph Maroon, MD, FACS to its Board of Directors. The Nevada-based company operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD, and a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and eight dollars total by Regal Consulting. LLC, for news commentary articles for CIIX. CIIX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.
For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States